Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 651 - 675 of 819 in total
Experimental
Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January...
Investigational
Experimental
A coenzyme A derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems.
Experimental
Experimental
Experimental
Experimental
Displaying drugs 651 - 675 of 819 in total